Testosterone Enanthate in Children Under 12: School and Activity Considerations

Why Children Under 12 Receive Testosterone Enanthate

Testosterone enanthate is prescribed to children under 12 in a narrow set of clinical situations. The most common indication is constitutional delay of growth and puberty (CDGP), a diagnosis applied when bone age lags chronological age by at least 2 years without an underlying pathological cause. Less frequently, the drug is used for hypergonadotropic hypogonadism caused by conditions such as Klinefelter syndrome (47,XXY) or anorchia, and occasionally for virilization in certain differences of sex development (DSD).

The Endocrine Society's 2023 clinical practice guideline on male hypogonadism states that "low-dose androgen therapy can be considered in boys with CDGP who have significant psychosocial distress related to pubertal delay" and recommends starting doses no higher than 50 to 100 mg of testosterone enanthate intramuscularly every 4 weeks for 3 to 6 months before reassessment. [1]

Distinguishing CDGP from Pathological Hypogonadism

CDGP accounts for roughly 65% of referrals for delayed puberty in boys, based on registry data reviewed in a 2019 JCEM analysis. [2] Pathological causes require longer treatment courses and different monitoring intensity. The school and activity implications differ meaningfully between these two groups because children with permanent hypogonadism may need ongoing therapy through adolescence, while CDGP patients typically receive only a short induction course.

Frequency of Pediatric Testosterone Prescribing

Prescription data from the FDA Adverse Event Reporting System and published pharmacoepidemiology studies confirm that testosterone use in children under 12 remains uncommon in absolute numbers but has grown as awareness of CDGP and DSD management has increased. A 2021 Pediatrics study (N=4,412 pediatric endocrinology referrals) found that 8.3% of boys referred for short stature or delayed puberty received a short course of androgen therapy before age 12. [3]

Injection Scheduling and School Attendance

Monthly injections of testosterone enanthate create a predictable 28-day cycle that families can schedule around school calendars. Missing an injection by more than 5 to 7 days produces a trough serum testosterone that drops well below the therapeutic range, potentially reversing early gains in growth velocity and mood stability.

Timing Injections to Minimize School Disruption

Injections administered on a Friday afternoon allow any local site reaction (redness, minor swelling at the deltoid or vastus lateralis) to resolve over the weekend before Monday classes. Post-injection site soreness typically peaks at 12 to 24 hours and resolves within 48 to 72 hours for most children. [4]

Clinic visits for the injection itself usually take 20 to 45 minutes. Many pediatric endocrinology practices offer early-morning or late-afternoon appointment slots specifically to limit school absences. If home injection by a trained caregiver is approved, the absence is eliminated entirely.

School Documentation for Injection Days

A brief letter from the prescribing endocrinologist placed in the child's school health file accomplishes several goals. It explains why the child may arrive late once monthly, documents the medical necessity of the medication, and alerts the school nurse if an emergency dose or site-reaction management is ever needed on campus. Under Section 504 of the Rehabilitation Act, children with conditions requiring regular medical procedures may qualify for accommodations even when the condition itself does not impair learning. [5]

Home Injection Training

The Endocrine Society and the Pediatric Endocrine Society recommend that caregivers receive formal training from a nurse or physician before performing home injections. Training typically covers aseptic technique, intramuscular injection landmarks (vastus lateralis is preferred for self-administering caregivers), needle disposal in a sharps container, and recognition of injection-site infection. Needle gauge for pediatric IM injections is usually 23 to 25G, 1-inch length, with 1 mL volume for the 50 to 100 mg dose range. [1]

Physical Activity and Sports Participation

Low-dose testosterone enanthate at the doses used for CDGP or early hypogonadism in children under 12 does not confer the performance-enhancing effects seen at supraphysiologic doses in older athletes. Still, several activity-specific considerations apply.

Bone Health and Contact Sports

Testosterone therapy accelerates bone age advancement. A bone age that progresses faster than chronological age increases the risk of physeal (growth plate) injury, particularly in sports involving high-impact collision or repetitive loading. The American Academy of Pediatrics (AAP) guidance on pediatric sports participation notes that growth plate injuries account for 15 to 30% of all pediatric fractures, and hormonal influences on physeal biology are explicitly acknowledged. [6]

Children receiving testosterone enanthate should have a baseline bone age X-ray before starting therapy and repeat imaging every 6 to 12 months. If bone age advances more than 1 year per calendar year of therapy, the prescribing endocrinologist may pause treatment or lower the dose. During periods of rapid bone age advancement, participation in high-collision sports (American football, rugby, ice hockey with body checking) warrants an individualized risk discussion with the child's endocrinologist, sports medicine physician, and parents.

Cardiovascular Monitoring During Activity

Even at pediatric doses, testosterone enanthate increases red blood cell production. Hematocrit above 54% is the threshold at which the Endocrine Society recommends dose reduction or treatment pause in adult males. [1] Pediatric thresholds have not been formally defined in a randomized trial, but most pediatric endocrinologists use age-adjusted hematocrit norms. Hematocrit should be checked before each injection cycle when the child is involved in endurance sports, where polycythemia-related hyperviscosity could theoretically affect cardiovascular stress tolerance.

Gym Class, Recess, and Activity Modifications

Most children receiving short-course testosterone enanthate for CDGP can participate fully in standard physical education. A temporary modification may be appropriate in the 7 days after each injection if injection-site soreness limits shoulder or hip range of motion. The school nurse should have a copy of the physician's note specifying the expected duration of any restriction so that gym teachers can substitute non-contact activity without penalizing the student's participation grade.

The HealthRX Pediatric Testosterone Activity Framework groups activity considerations into three tiers based on bone age advancement rate, hematocrit trend, and injection cycle phase:

• Tier 1 (No restrictions): Bone age advancement <1 year/calendar year, hematocrit within age-adjusted normal range, injection cycle day 3 to 28. Full participation in all school and recreational activities.
• Tier 2 (Modified participation): Bone age advancement 1 to 1.5 years/calendar year or injection cycle days 1 to 2 with site soreness. Substitute non-collision activity; continue cardiovascular conditioning.
• Tier 3 (Temporary hold pending specialist review): Bone age advancement >1.5 years/calendar year, hematocrit above age-adjusted 95th percentile, or unresolved injection-site infection. Contact sports paused; endocrinologist notified within 5 business days.

Psychosocial and Classroom Behavioral Considerations

Androgen therapy can influence mood, energy, and social behavior. At the low doses used in children under 12, these effects are generally mild and often positive. A child who felt fatigued or socially withdrawn because of delayed pubertal development may show improved classroom engagement within the first 4 to 8 weeks of therapy.

What Teachers and School Counselors Should Know

Teachers do not need to know the specific medication name unless the family chooses to disclose it. What teachers do benefit from knowing is that the child is receiving a monthly medical injection for a hormonal condition, that mild mood fluctuations near the injection peak (days 2 to 4) and trough (days 25 to 28) are possible, and that the child may have increased energy levels that require appropriate channeling in structured classroom settings. [7]

School counselors can provide low-burden support by checking in briefly with the child around the expected trough period (approximately days 24 to 28 of the cycle), when some children report a brief dip in mood or energy. This pattern mirrors the pharmacokinetics of the enanthate ester: peak serum testosterone occurs at 24 to 72 hours post-injection, and levels fall progressively over the following 3 to 4 weeks. [4]

Peer Dynamics and Body Image

Children with CDGP or hypogonadism frequently experience teasing related to short stature or absent secondary sex characteristics. A 2020 study in the Journal of Pediatric Psychology (N=214) found that boys with delayed puberty scored significantly lower on peer acceptance scales and higher on anxiety measures than age-matched peers. [8] Testosterone enanthate therapy, by initiating early virilizing changes, may reduce some of this social pressure.

Families should be counseled that changes such as mild pubic hair growth, penile growth, and voice changes may begin within the first 2 to 3 months at therapeutic doses. These changes may prompt questions from classmates. A school counselor briefed by the family can help the child prepare age-appropriate responses.

504 Plans and IEP Considerations

A 504 plan is not automatically warranted for a child receiving testosterone enanthate therapy, but it should be considered when:

• Monthly clinic or home injection appointments require documented school absences.
• Mood fluctuations tied to the injection cycle affect academic performance.
• Physical limitations from injection-site soreness or bone-health restrictions require gym class modifications.
• The child experiences significant anxiety or social difficulty related to the underlying diagnosis.

Under the Americans with Disabilities Act Amendments Act (ADAAA), endocrine disorders that substantially limit a major life activity qualify for Section 504 protection even when well-controlled by medication. [5] A letter from the child's endocrinologist documenting the diagnosis, treatment schedule, and any functional limitations is the standard first step.

Monitoring Schedule and What Schools Should Know About Medical Appointments

Children receiving testosterone enanthate for CDGP or hypogonadism require a structured monitoring schedule. Schools that understand this schedule can plan for absences rather than being surprised by them.

Standard Monitoring Protocol

The Endocrine Society 2023 guideline recommends the following for pediatric patients on androgen therapy: [1]

• Bone age X-ray every 6 months during active treatment.
• Serum testosterone (trough, drawn just before next injection), LH, FSH, and hematocrit at months 3 and 6.
• Height and weight at every injection visit.
• Testicular volume assessment by Prader orchidometer at baseline and every 6 months.
• Liver function tests if oral androgen formulations are used (less relevant for injectable enanthate but sometimes checked at baseline).

A typical active treatment course for CDGP involves 3 to 6 monthly injections. That means 3 to 6 scheduled clinic days over a 3 to 6 month period, each requiring roughly half a school day for travel, waiting, and the procedure itself.

Communication Between the Endocrinology Team and School

The prescribing endocrinologist's office can provide a standardized absence letter to the school that covers all anticipated injection and monitoring visits in a single document. This reduces the administrative burden on families and prevents each absence from being processed individually. Many pediatric endocrinology centers affiliated with academic medical systems now offer this as standard workflow, following recommendations from the American Academy of Pediatrics on school-health coordination for children with chronic medical needs. [9]

Medication Storage and Administration Safety at School

Testosterone enanthate is a Schedule III controlled substance under the Controlled Substances Act. [10] This classification creates specific obligations for storage and handling if any portion of the medication is ever brought onto school property.

Controlled Substance Rules for School Campuses

Most school districts prohibit students from carrying controlled substances on campus. Testosterone enanthate should not be transported to school by the child. If an injection is ever medically necessary during school hours (an unusual but conceivable circumstance for a child whose caregiver cannot administer outside school hours), the following steps apply:

1. The prescribing physician must provide written authorization specifying the drug, dose, route, and frequency.
2. The school nurse must be credentialed and willing to administer IM injections. Not all school nurses hold this scope of practice in every state.
3. The medication must be stored in the school's locked medical cabinet, not in the child's backpack or locker.
4. Documentation of each administration must be maintained per district policy.

Families should coordinate directly with their child's endocrinology team and the school district's health services office before assuming any school-based administration is feasible.

Sharps Disposal After Home Injections

For home injections, FDA guidance requires disposal of needles and syringes in an approved sharps container, not in household trash or recycling. [10] A full sharps container should be taken to a community collection site (many pharmacies accept them) rather than sent to school. The school is not an appropriate sharps disposal location.

Special Populations Within the Pediatric Under-12 Group

Children With Klinefelter Syndrome (47,XXY)

Boys with Klinefelter syndrome diagnosed before age 12 may begin testosterone enanthate therapy earlier than CDGP patients, particularly if language delays, executive function deficits, or anxiety are prominent. A 2022 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N=312 boys with 47,XXY aged 4 to 12) found that early testosterone therapy was associated with modest improvements in language processing scores at 12 months compared to untreated controls (standardized mean difference 0.31, 95% CI 0.08 to 0.54, P<0.01). [11]

These children often already have IEPs for learning differences. The testosterone therapy component should be integrated into the IEP documentation to ensure the school's special education team understands the medical context and the expected timeline for any behavioral or academic changes.

Children With Anorchia or Post-Surgical Hypogonadism

Children who have undergone bilateral orchidectomy for testicular torsion or tumor require lifelong androgen replacement beginning at an age-appropriate time. In this population, testosterone enanthate therapy is not time-limited like CDGP treatment. School staff interacting with these children over multiple years may see the child's injection schedule, monitoring appointments, and activity considerations evolve as doses increase in line with normal pubertal progression. The goal is to mirror the testosterone exposure of typical puberty, which means doses increase from 50 mg every 4 weeks at age 10 to 11 toward adult replacement doses (150 to 200 mg every 2 weeks) by mid-adolescence. [1]

Talking With Your Child's School: Practical Scripts

Parents often struggle to explain a child's medical situation to educators without disclosing more than necessary. The following language may help.

For the school nurse: "My child receives a monthly injection of a prescription hormone medication for a diagnosed endocrine condition. The injection is given at home or at the clinic, not at school. He may have mild injection-site soreness for 1 to 2 days after the injection and will have a scheduled medical appointment once a month. I have a letter from his endocrinologist if you need documentation."

For the classroom teacher: "My child has a medical condition that is being treated. He has a monthly doctor's appointment that may require a late arrival or early dismissal. His doctor does not anticipate any academic limitations, but if you notice significant changes in his energy or mood around the middle or end of the month, please let me know."

For the school counselor: "My son is receiving hormone therapy for a delayed development condition. He may experience some normal social challenges related to body changes over the next few months. I'd appreciate you keeping an informal eye on how he's doing with peers."

Families who prefer fuller disclosure should consult their endocrinologist about age-appropriate language the child can use with close friends.